Julian Baker

Filings by Julian Baker span 6 companies, the busiest being Incyte Corp, Genomic Health Inc and Idera Pharmaceuticals, Inc. Over a trading history stretching from 25 April 2006 to 17 February 2017, the count stands at 240 filings.

Market trades split into 131 purchases (€500.8M) and 9 sales (€13k). Taken together, the purchases exceed the sales by €500.8M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 61 share grants and 19 option exercises.

The median purchase comes to €625k. Of 66 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 64 purchases with a full 90-day history, the hit rate stands at 100% and the median 90-day move at +1.5%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 22 February 2017: a share grant, in Incyte Corp. The latest purchase dates back some time: it was published 3,680 days ago, on 11 October 2016. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.